with the highest genetic barrier to resistance, and maraviroc, the first CCR5 inhibitor, were approved in 2006. Raltegravir (RAL; Merck Laboratories), the first integrase inhibitor (INI), was approved in 2007, and etravirine, the first non-nucleoside reverse transcriptase inhibitor (NNRTI) shown to be useful for treating patients in whom previous NNRTIs were ineffective, was approved in 2008. Of these 4 new ARVs, the development of RAL may have had the greatest effect on current ARV treatment strategies.
RAL, however, may not be unique among INIs. Two other INIs in advanced clinical development-elvitegravir (EVG; Gilead Sciences) and S/GSK1349572 (GlaxoSmithKline)-may be equally efficacious. However, resistance to RAL and EVG develops rapidly in vitro and, in the absence of other active ARVs, in vivo. Although S/GSK1349572, which is earlier in its clinical development than EVG, appears to have a higher genetic barrier to resistance than RAL or EVG, its efficacy at treating RAL-resistant viruses is incomplete. Understanding INI resistance is therefore critical to use of INIs for initial therapy, the treatment of ARV-experienced patients, and regimen simplification.
INTEGRASE STRUCTURE AND FUNCTION AND INHIBITOR DISCOVERY
Following reverse transcription, integrase (IN) cleaves the conserved dinucleotides GT from the 3# ends of double-stranded HIV-1 DNA, leaving 2 CA overhangs (the 3#-processing reaction). IN remains bound to each of the 3# ends, circularizing the HIV-1 preintegration complex (PIC). IN then binds the host protein, lens epithelialderived growth factor (LEDGF), which translocates the PIC to the nucleus, where IN catalyzes a nucleophilic attack of the viral 3#-hydroxy ends on the phosphodiester bonds of host genomic DNA (the strandtransfer reaction). Although IN catalyzes both the 3#-processing and strand-transfer reactions, only those compounds that specifically inhibit strand transfer have been effective INIs. Indeed, the development of a high-throughput screening assay for the identification of strand-transfer inhibitors that bind IN in complex with viral DNA heralded the modern era of INI development [1] .
HIV-1 IN contains 288 amino acids encoded by the 3# end of the HIV-1 pol gene. It is composed of 3 functional domains. The catalytic core domain (CCD), which encompasses amino acids 51 to 212, contains the catalytic triad D64, D116, and E152 and the viral DNA binding site. D64 and D116 coordinate the positioning of a metallic cationic cofactor (Mg 11 or Mn
11
), which is essential for IN function. The N-terminal domain (NTD), which encompasses amino acids 1 to 50, is characterized by an HHCC zinc-binding motif. Its primary role appears to be to facilitate IN multimerization through its extensive contacts with adjacent CCD monomers. The C-terminal domain (CTD), which encompasses amino acids 213 to 288, binds host DNA nonspecifically.
There are published crystal structures of the HIV-1 IN CCD plus CTD domains, the CCD plus NTD domains, the CCD bound to LEDGF, and the CCD bound to an active site inhibitor, the prototype diketo acid inhibitor 5CITEP (reviewed in [2] [3] [4] ; see Figure 1 ). But the relative conformation of the CCD, NTD, and CTD domains and the tetrameric state of functional HIV-1 IN has been inferred primarily from crystallographic studies of the homologous IN of the prototype foamy virus (PFV) [5] . The applicability of the PFV IN structure to HIV-1 IN is validated by the consistency of the PFV IN structure with HIV-1 IN biochemical data and by the ability of PFV IN to co-crystallize with RAL and EVG [5] [6] .
HIV-1 IN inhibitors are structurally diverse molecules that contain a motif for binding the essential divalent metal cations Mg 11 or Mn 11 and a hydrophobic region for binding within the cavity formed by integrase and the 3# HIV-1 DNA ends containing the terminal CA dinucleotide. RAL, EVG, and S/GSK1349572 displace viral DNA in the active site and contact several active site amino acids-including those in a mobile loop extending between positions 140 and 149 [2] [3] [4] . [9] [10] , EVG [7] [8] [9] , or 572 [11] ; (2) in vivo data on mutations that emerged in individuals receiving RAL [12] [13] [14] [15] [16] [17] [18] [19] or EVG [20] ; and (3) in vitro susceptibility data of site-directed mutants and clinical HIV-1 isolates to RAL, EVG, and S/GSK1349572 [7-11, 18, 21-23] . Nineteen mutations at 10 positions (T66IAK, E92QV, F121Y,  Y143RCH, P145S, Q146P, S147G [28, 31] ). Table 2 shows the most common patterns of INI resistance mutations in published HIV-1 IN sequences from individuals receiving RAL [32] . Among 192 viral isolates from 105 RAL-treated individuals, 121 viruses contained mutations belonging to one of the 3 most commonly reported RAL-resistance mutation pathways: (1) Q148HRK 6 G140SA (n 5 58), (2) N155H 6 E92Q (n 5 38), and (3) Y143CR 6 T97A (n 5 25). The remaining 71 viruses from 44 individuals included 50 viruses without primary INI resistance mutations, 18 viruses with mutations belonging to more than one of the 3 most common mutational pathways, and 3 with primary mutations not belonging to any of the 3 common mutational pathways. Despite the fact that one mutation such as Y143R, Q148HKR, or N155H is often sufficient to reduce RAL susceptibility more than 10-fold-particularly in site-directed mutagenesis experiments-most RAL-resistant viruses obtained from RAL-treated patients have 2 or more RAL resistance mutations.
INTEGRASE INHIBITOR RESISTANCE
Most published INI susceptibility data have been produced by Monogram's PhenoSense assay, Virco's Antivirogram assay, and various permutations of HeLa-CD4 1 reporter gene assays. Although these assays frequently yield divergent results, the relative reductions in susceptibility associated with different mutation patterns is consistent among the different assays. Q148 is a critical part of the IN active site believed to interact with the terminal adenosine and preterminal cytosine of the reactive viral DNA strand. Q148HRK decreases susceptibility to each of the INIs but also markedly decreases IN function. The replication defect associated with Q148HKR, however, is largely reversed by mutations at position 140 and, to a lesser extent, at position 138 [21, 24] . In clinical isolates, viruses with Q148 plus G140 mutations have .150-fold reduced susceptibility to RAL and EVG and up to 10-to 20-fold reduced susceptibility to S/GSK1349572 particularly when a third INI resistance mutation is also present ( Table 2) .
The second-most common pathway to RAL resistance includes N155H. N155H lies at the base of the catalytic site, where it may form a hydrogen bond with the active site residue E152 and directly interfere with IN metal binding [2] . N155H reduces susceptibility to RAL and EVG but not S/GSK1349572. N155H alone decreases replication capacity less than that of viruses with Q148 mutations alone. The addition of E92Q to N155H further decreases RAL and EVG susceptibility but does not rescue viral fitness [21] . Therefore, viruses with N155H 6 E92Q are often outcompeted by viruses with G140 1 Q148 mutations [21, 24] .
Y143RC is the third-most common pathway to RAL resistance. When RAL binds IN, it induces a stacking interaction with Y143 [5, 34] . Substitution of Y with C or R removes this favorable interaction. S/GSK1349572 and EVG do not appear to contact Y143, and viral susceptibility to these INIs is not affected by Y143 mutations (Table  2) . T97A markedly increases Y143RC-mediated RAL resistance [18, 21] . Y143H usually occurs as part of an electrophoretic mixture and may represent a transition between Y and
The Genetic Barrier to INI Resistance
The genetic barrier to INI resistance is lower than that of the PIs and most NRTIs. First, INI resistance is usually selected more rapidly during in vitro passage experiments with INIs than with most NRTIs and PIs [7] [8] [9] [10] . Second, virological failure on an INI-containing regimen often occurs within the first several months of therapy and is often accompanied by INI resistance mutations [12, 19, 35] . In Merck Protocol 005, 35 of Figure 1 . HIV-1 integrase (IN) inhibitor resistance mutations superimposed on a crystal structure of the IN central core domain bound to a prototype diketo acid inhibitor (5CITEP; PDB 1QS4) [54] . IN residues 56 to 165 are displayed in gray cartoon mode to represent secondary structural properties. 5CITEP is represented using cyan spheres. Active site residues D64, D116, and D152 are in white. Sites associated with the most commonly occurring primary mutations are in red (T66, E92, G140, S147, Q148, and N155). Sites associated with the most common accessory mutations (L74, T97, E138, V151, S153, and S163) and with primary mutations that have been observed solely in vitro (F121, Q145, and P146) are in yellow. Mg 11 is a blue sphere. Residues 141 to 144, which form part of the highly mobile loop extending between G140 and G149, were not resolved in this crystal structure. [7] and rarely in vivo by RAL [13] .
38 subjects with virological failure developed RAL-resistant viruses [35] , and in the BENCHMRK trials 64 of 94 with virological failure who underwent genotypic resistance testing had RAL-resistant viruses [12] . Likewise, a high proportion of subjects who developed virological failure while receiving EVG in the phase II trial GS-153-105 developed EVGresistant viruses [2] . Third, the substitution of RAL for lopinavir/ritonavir (LPV/r) in the SWITCHMRK trial in patients with stably suppressed HIV-1 infection was associated with an increased risk of virological rebound [36] . Fourth, although RAL resistance mutations have been associated with decreased replication capacity [25] [26] , no clinical benefit has been observed from continuing RAL in patients with high-level RAL resistance [37] , presumably because most primary RAL resistance mutations occur in combination with accessory compensatory mutations [24] [25] [26] .
The genetic barrier to INI resistance, however, may not be as low as that of lamivudine, emtricitabine, or the NNRTIs nevirapine and efavirenz. In contrast to the NNRTIs, RAL has been highly effective at treating ARVexperienced individuals with few therapeutic options. In the BENCHMRK trials, RAL-containing regimens often NOTE. *Direct PCR sequences of HIV-1 group M plasma viruses from 4,435 INI-naive individuals [29] . The RAL-Rx % is the no. of patients with a virus sequence containing a mutation divided by the number of RAL-treated patients (n 5 105) obtained from 12 published references in the Stanford HIV Drug Resistance Database [32] . Although several RAL-treated individuals had multiple sequences, no mutation was counted more than once per individual. In vitro susceptibility in the absence of other INI resistance mutations. Most data were derived from site-directed mutants. When data were available from multiple studies or determined using multiple assays the fold resistance approximates the median of the multiple results.
§ S-1360, L-870,812, and GS-9160 are investigational INIs.
{ Site-directed mutants with Q148H, Q148R, or Q148K do not decrease 572 susceptibility. However, viruses having one of these mutations in combination with E138K and/or G140S may have up to 10-to 20-fold decreased 572 susceptibility [11, 33] . *G140SA and T97A are in this column because of their strong association with Q148 and Y143 mutations, respectively. Accessory mutations include the mutations in the second half of Table 1 (except G140SA and T97A). Viruses with primary mutations belonging to more than one pathway are not shown. The totals of these 2 columns consist of 121 viruses containing one of the 3 most common raltegravir-associated mutational patterns.
§ In vitro susceptibility data obtained using the PhenoSense assay, the Antivirogram, or one of the generic HeLa-CD4 1 reporter gene assay variants. Viruses containing G140 1 Q148 mutations may have up 10-to 20-fold decreased S/GSK1349572 susceptibility when a third INI resistance mutation is present [11, 33] . Five of 6 RAL-treated subjects with VF and plasma HIV-1 RNA levels .400 copies/mL developed RAL resistance. PROGRESS [44] Phase III randomized blinded study of RAL 1 LPV/r (n5 101) vs. TDF/FTC 1 LPV/r BID (n 5 105)
One of 4 RAL-treated subjects with VF and plasma HIV-1 RNA levels .400 copies/mL developed RAL resistance.
Regimen Simplification EASIER [45]
Phase III randomized open-label trial of RAL vs. continued enfuvirtide in subjects with plasma HIV-1 RNA levels ,400 copies/ mL for >3 months At week 24, 88% of subjects in both arms had plasma HIV-1 RNA levels ,50 copies/mL. INI resistance mutations emerged in 3 of 39 subjects with low-level viremia (defined as plasma HIV-1 RNA levels ,1,000 copies/mL (Table 3 ). It has also been extremely difficult to select for S/GSK1349572 resistance in vitro, The EVG 20 mg arm was discontinued at week 8. The 125 mg EVG dosage regimen produced a significantly greater decrease in plasma HIV-1 RNA levels than the comparator RTVboosted PI arm. However, plasma HIV-1 RNA levels ,50 copies/mL occurred mainly in those EVG recipients who also received enfuvirtide or subsequently added TPV or DRV. EVG resistance occurred commonly among EVG recipients with VF.
Late-Stage Therapy: INI Experienced
VIKING [33] Phase II single-arm study of 572 50 mg QD as RAL replacement 3 10 days followed by 572 50 mg 1 OBR 3 23 weeks (n5 27). The initial primary end point was a plasma HIV-1 RNA decrease >.7 logs by day 11.
In the 18 subjects with viruses having mutations belonging to the N155H or Y143 pathways, the mean plasma HIV-1 RNA decrease by day 11 was 1.8 log copies/mL. Three of 5 subjects with Q148H 1 G140S had an RNA decrease >.7 logs by day 11. None of 4 subjects with a Q148 mutation plus >2 additional mutations at positions 74, 138, and 140 had an RNA decrease >.7 logs.
NOTE. RAL, raltegravir; EVG, elvitegravir; 572, S/GSK1349572; TDF, tenofovir; 3TC, lamivudine; FTC, emtricitabine; EFV, efavirenz; RTV, ritonavir; ATV, atazanavir; TPV, tipranavir; DRV, darunavir; LPV/r, lopinavir/ritonavir; ARV, antiretroviral; BID, twice daily; INI, integrase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; OBR, optimized background regimen; PI, protease inhibitor; QD, once daily; VF, virological >failure.
*Clinical trials are ordered according to their year of publication. Raltegravir dosage was 400 mg twice daily unless otherwise specified. Other regimens and antiretrovirals were used at standard dosages unless otherwise specified.
suggesting that this INI has a higher genetic barrier to resistance than RAL or EVG [11] .
INI Cross-Resistance
The 2 most commonly occurring RA-L-associated mutation pathways-Q148HRK 1 G140SAC and N155H 6 E92Q-both cause high-level EVG resistance. In contrast, the third RALassociated mutation pathway, Y143CR 6 T97A, does not confer EVG crossresistance. Similarly, the common EVGassociated resistance mutations T66I [8] [9] and S147G [2, 7] do not confer RAL cross-resistance. S/GSK1349572 is fully active in vitro against viruses with N155H 6 E92Q or Y143CR 6 T97A. However, susceptibility to S/GSK1349572 is reduced by about 10-to 20-fold by mutations at positions Q148HRK 6 G140SAC 6 E138KA [11, 33] .
CLINICAL IMPLICATIONS OF INTEGRASE INHIBITOR RESISTANCE
RAL was first approved because of its effectiveness in the treatment of 3-and 4-class experienced HIV-infected individuals. It was subsequently approved for first-line therapy because of the noninferiority of tenofovir (TDF) 1 emtricitabine (FTC) 1 RAL compared with the standard-of-care first-line regimen TDF 1 FTC 1 efavirenz (EFV). RAL has since found a third role as a well-tolerated substitute for enfuvirtide or ritonavir-boosted PIs in patients with stable virological suppression (''regimen simplification'').
The novel stage at which INIs block HIV-1 replication has prompted intensification studies designed to eradicate HIV-1 from long-lived cellular reservoirs or to eliminate low-level residual viremia that emanates from this reservoir. These studies have shown that RAL intensification does not appear to reduce the size of the latent virus reservoir or eliminate low-level residual viremia [50] [51] [52] . One study has shown that in some patients the latent HIV-1 reservoir is replenished by ongoing low-level replication because telltale episomal viral forms accumulate in some patients receiving RAL intensification [53] .
Initial ARV Therapy Table 3 summarizes published clinical trials in which INIs were used for initial ARV therapy [38] [39] [41] [42] [43] [44] . In the phase III STARTMRK trials, RAL 1 TDF/FTC twice daily was as effective as the standard-of-care regimen (EFV 1 TDF/FTC once daily) [39] . As a result, published guidelines have recommended RAL 1 TDF/FTC as a preferred first-line regimen.
In a viral dynamic substudy of the phase II trial Protocol 004 [38] , RALcontaining treatment was shown to accelerate the decline in plasma HIV-1 RNA levels relative to EFV-containing treatment. The accelerated decline in virus levels appears to result from INIinduced prevention of the release and production of virions from cells with unintegrated forms of HIV-1 DNA. This accelerated decline, however, has not been shown to provide a unique clinical benefit presumably because the longer period of detectable viremia in patients not receiving INIs is caused by virions produced from unintegrated viral DNA that are unable to infect new cells in the presence of active reverse transcriptase or protease inhibition.
In an interim 48-week analysis of the phase IIb trial comparing 48 subjects receiving EVG 1 cobicistat (an investigational pharmacokinetic enhancer) 1 TDF/FTC with 23 subjects receiving EFV 1 TDF/FTC, the EVG-and EFVcontaining arms demonstrated similar virological efficacy [41] . In a doseranging 24-week phase II study of S/ GSK1349572, at least 90% of subjects receiving each of the 3 S/GSK1349572 dosages had plasma HIV-1 RNA levels below 50 copies/mL [42] .
In the NRTI-sparing PROGRESS trial, RAL 400 mg BID 1 LPV/r 400/100 mg BID produced virological responses similar to the standard-of-care regimen TDF/FTC 1 LPV/r 400/100 mg BID [44] (Table 3) . Four subjects in the RALcontaining arm met the protocol-defined criteria for virological failure and genotypic resistance testing, and one had INI resistance. In the 24-week NRTIsparing SPARTAN trial, open-label RAL 400 mg BID 1 atazanavir (ATV) 300 mg BID in 63 patients was similar in efficacy to the standard-of-care arm (ATV/r 1 TDF/FTC) [43] . However, among the 11 RAL recipients with virological failure, 5 developed RAL resistance, suggesting that despite the clinical efficacy of RAL 1 ATV, the regimen may be associated with a higher risk of INI resistance at the time of virological failure. The clinical trial was halted because of the frequent occurrence of INI resistance and hyperbilirubinemia [43] .
Regimen Simplification
One controlled comparative trial [45] and multiple open-label pilot studies have shown that patients with stable virological suppression on an enfuvirtidecontaining regimen can substitute RAL for enfuvirtide without risking virological rebound. The substitution of RAL for a boosted PI, however, has not been uniformly successful. In the large randomized double-blinded controlled SWITCHMRK trial, RAL regimen simplification was less efficacious than continued LPV/r: 84% of 353 RAL recipients versus 91% of 354 suppressed subjects continuing LPV/r maintained a plasma HIV-1 RNA level of fewer than 50 copies/mL by week 24 [36] . Moreover, 8 of the 11 RAL recipients with virological failure developed RAL resistance. In contrast, in the phase IV open-label SPIRAL trial, RAL substitution was at least as efficacious as the boosted PI arm: 89% versus 87% of subjects, respectively, maintained plasma HIV-1 RNA levels of fewer than 50 copies/mL over the 48-week study period [46] .
The higher risk of virological failure associated with RAL in the SWITCHMRK compared with the SPI-RAL trial is consistent with the observation that failure in SWITCHMRK was associated with previous NRTI failure, so LPV/r was more effective than RAL in the context of a compromised background regimen. In contrast, in the SPIRAL trial about one-half of the subjects in the comparator arm received ATV/r and fosamprenavir/r, PIs with a lower genetic barrier to resistance than LPV/r. Subjects in the SPIRAL trial also had a longer baseline history of virological suppression (>6 months versus >3 months) than those in the SWITCHMRK trial, placing the SPIRAL trial participants at a lower risk of virological failure.
ARV-Experienced Patients
The phase III randomized double-blind controlled BENCHMRK trial demonstrated the efficacy of RAL for highly ARV-experienced patients ( Table 3) . The phase II GS-183-105 trial compared several different ritonavir-boosted EVG (EVG/r) dosages with an optimized ritonavir-boosted PI-containing regimen. In GS-183-105, the superiority of EVG/r relative to the comparator arm was less than that in the BENCHMRK trials because in GS-183-105, EVG/r was compared with a boosted PI and an optimized background regimen. In contrast, in the BENCHMRK trials, RAL was compared solely with an optimized background regimen. A double-blinded phase III study directly comparing the safety and efficacy of EVG/r with RAL has been fully enrolled (NCT00708162).
Although the treatment of highly ARV-experienced patients with ARV regimens containing RAL or EVG has been successful in the majority of patients in these trials, virological failure and INI resistance occurred in a large proportion of subjects whose optimized background regimen contained no additional active ARVs. The successful use of RAL for treating highly ARV-experienced patients in clinical practice has also been high, particularly when it is part of a regimen containing one or more recently approved ARVs such as darunavir, maraviroc, or etravirine [49] .
The VIKING trial is a phase II single-arm study of S/GSK1349572 QD administered to subjects with RALresistant viruses in whom a previous RAL-containing regimen had been unsuccessful [33] . For the first 10 days of the trial, S/GSK1349572 was given as functional monotherapy (ie, in combination with existing ARVs for those subjects who had already discontinued RAL or as replacement for RAL for those subjects still receiving it). In the 18 subjects with viruses having mutations in the N155 or Y143 mutational pathways, the mean RNA decrease was 1.8 logs by day 11. In contrast, the virological response was poorer in patients with viruses having Q148 pathway mutations. Although 3 of 5 subjects with Q148H 1 G140S had an RNA decrease >.7 logs by day 11 (the primary end point), none of 4 subjects with a Q148 mutation plus 2 or more additional mutations at positions 74, 138, and 140 had an RNA decrease >.7 logs. Whether or not the 10-to 20-fold decreased susceptibility to S/ GSK1349572 associated with a Q148 mutation plus one or more mutations can be overcome with a higher S/ GSK1349572 dosage (50 mg twice daily) is being evaluated in a second cohort of this trial (NCT00950859; http://clinicaltrials.gov).
There have been no studies of RAL or EVG in patients infected with viruses containing INI resistance mutations or having a history of previous INI therapy. Therefore, there are no clinically validated genotypic susceptibility scores or phenotypic cutoffs yet for these INIs. However, treatment with RAL is unlikely to be effective at treating viruses containing one of the major RAL resistance mutations such as Y143CR, Q148HRK, and N155H. Likewise, treatment with EVG is unlikely to be effective at treating viruses containing one of the major EVG resistance mutations such as T66IAK, E92Q, S147G, Q148HRK, and N155H.
CONCLUSIONS
The potency and tolerability of RAL have made it an important option for first-line therapy, the treatment of highly ARV-experienced patients, and regimen simplification. RAL's relatively low genetic barrier to resistance, coupled with the high level of cross-resistance within the INI class, calls for clinicians to be familiar with the studies that define RAL's optimal use. The investigational INIs EVG and S/GSK1349572 are also being studied for first-line therapy and the treatment of highly ARV-experienced patients. If these INIs are approved and prove to be as well tolerated as RAL, they are also likely to be used for regimen simplification. S/GSK1349572 may also prove useful at treating a significant subset of patients who have RALresistant viruses.
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